EMA Authorised: Ocrevus (ocrelizumab) — Roche Registration GmbH

View source ↗

Summary

The European Medicines Agency authorised Ocrevus (ocrelizumab) for treating multiple sclerosis, with Roche Registration GmbH as the marketing authorisation hold…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis. MAH: Roche Registration GmbH. Decision date: 29/04/2025